Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Income: 2021-2025

Historic Operating Income for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $24.0 million.

  • Kiniksa Pharmaceuticals International's Operating Income rose 348.72% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year increase of 245.43%. This contributed to the annual value of -$45.6 million for FY2024, which is 81.04% down from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Operating Income stood at $24.0 million, which was up 19.15% from $20.2 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Operating Income's 5-year high stood at $46.4 million during Q3 2022, with a 5-year trough of -$49.3 million in Q1 2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Operating Income had a median value of -$3.2 million in 2023 and averaged -$1.2 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Operating Income plummeted by 23,925.93% in 2024, and later surged by 17,330.77% in 2025.
  • Kiniksa Pharmaceuticals International's Operating Income (Quarterly) stood at -$36.1 million in 2021, then skyrocketed by 116.74% to $6.0 million in 2022, then crashed by 98.66% to $81,000 in 2023, then plummeted by 23,925.93% to -$19.3 million in 2024, then skyrocketed by 348.72% to $24.0 million in 2025.
  • Its Operating Income was $24.0 million in Q3 2025, compared to $20.2 million in Q2 2025 and $13.3 million in Q1 2025.